CLO Gina Mazzariello sold 30,000 shares ($538.9K) via 10b5-1 plan; retains 179.1K shares post-sale
Gina Mazzariello, Chief Legal Officer at Amylyx Pharmaceuticals, executed 2 separate sales totaling 30,000 shares for $538,867.50 on 2026-07-09 and 2026-07-10 at blended average price of $17.96. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-04-09, meaning the sales were scheduled and not discretionary. The stock currently trades at $17.41, within the 52-week range of $6.56–$19.15, and is -9.1% from the 52-week high. The company reported zero revenue in its latest quarter and negative net income of $-41,284,000.00, with annual revenue growth of -100.0%. Given the scheduled nature of the 10b5-1 plan, this transaction reflects pre-established execution rather than a real-time discretionary response to current operational or market conditions. Investors should note that the CLO retained 179,090 shares post-transaction and that the company's fundamental performance shows significant challenges including no reported quarterly revenue and substantial operating losses.